Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Lee Memorial Health System
1209
mi
from
Fort Myers, FL
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Lee Memorial Health System
1209
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Florida Health Science Center ?? Gainesville
1049
mi
from
Gainesville, FL
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Florida Health Science Center ?? Gainesville
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic - Orlando
1142
mi
from
Orlando, FL
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic - Orlando
1142
mi
from
Orlando, FL
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Cancer Center
3717
mi
from
Honolulu, HI
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Cancer Center
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Tulane University Health Sciences Center
697
mi
from
New Orleans, LA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Tulane University Health Sciences Center
697
mi
from
New Orleans, LA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
1285
mi
from
Hackensack, NJ
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
1285
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
1294
mi
from
Bronx, NY
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
1294
mi
from
Bronx, NY
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Memorial Health University Medical Center
1026
mi
from
Savannah, GA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Memorial Health University Medical Center
1026
mi
from
Savannah, GA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Downey Medical Center
1165
mi
from
Downey, CA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Downey Medical Center
1165
mi
from
Downey, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Valley Children's Hospital
1219
mi
from
Madera, CA
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Valley Children's Hospital
1219
mi
from
Madera, CA
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
960
mi
from
Las Vegas, NV
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
960
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospitals and Clinics
197
mi
from
Kansas City, MO
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospitals and Clinics
197
mi
from
Kansas City, MO
Click here to add this to my saved trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
1290
mi
from
New York, NY
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
1290
mi
from
New York, NY
Click here to add this to my saved trials
Botulinum Toxin for Pelvic Pain in Women With Endometriosis
The Effectiveness of Botulinum Toxin on Persistent Pelvic Pain in Women With Endometriosis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Botulinum Toxin for Pelvic Pain in Women With Endometriosis
The Effectiveness of Botulinum Toxin on Persistent Pelvic Pain in Women With Endometriosis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Follicular Flushing
Follicular Flushing on Cycle Outcomes in Poor Responders
Status: Enrolling
Updated:  12/31/1969
New York-Presbyterian Hospital
1290
mi
from
New York, NY
Follicular Flushing
Follicular Flushing on Cycle Outcomes in Poor Responders
Status: Enrolling
Updated: 12/31/1969
New York-Presbyterian Hospital
1290
mi
from
New York, NY
Click here to add this to my saved trials
Supportive Intervention Programs Study
Supportive Intervention Programs to Lessen Treatment Related Symptoms
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
Supportive Intervention Programs Study
Supportive Intervention Programs to Lessen Treatment Related Symptoms
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
979
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
Taurine Therapy for SSADH Deficiency
Succinic Semialdehyde Dehydrogenase Deficiency: Physiological Markers of Taurine Therapy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Taurine Therapy for SSADH Deficiency
Succinic Semialdehyde Dehydrogenase Deficiency: Physiological Markers of Taurine Therapy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
Acceptance and Commitment Therapy for Adolescents and Adults With Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
Acceptance and Commitment Therapy for Adolescents and Adults With Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Status: Enrolling
Updated:  12/31/1969
Joseph Losee, MD
974
mi
from
Pittsburgh, PA
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Status: Enrolling
Updated: 12/31/1969
Joseph Losee, MD
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
974
mi
from
Pittsburgh, PA
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Osteogenic Profiling of Tissue From Children With Craniosynostosis
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vitamin D, Cardiovascular Disease, and African Americans
Vitamin D and Early Markers of Cardiovascular Disease in African Americans
Status: Enrolling
Updated:  12/31/1969
Washington University
413
mi
from
Saint Louis, MO
Vitamin D, Cardiovascular Disease, and African Americans
Vitamin D and Early Markers of Cardiovascular Disease in African Americans
Status: Enrolling
Updated: 12/31/1969
Washington University
413
mi
from
Saint Louis, MO
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Ann & Robert Lurie Children's Hospital of Chicago
610
mi
from
Chicago, IL
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Ann & Robert Lurie Children's Hospital of Chicago
610
mi
from
Chicago, IL
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
University of Iowa
428
mi
from
Iowa City, IA
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
University of Iowa
428
mi
from
Iowa City, IA
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins
1149
mi
from
Baltimore, MD
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute
1123
mi
from
Bethesda, MD
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
University of Michigan
808
mi
from
Ann Arbor, MI
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
University of Michigan
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Pennsylvania Oncology Hematology Associates
1226
mi
from
Philadelphia, PA
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Pennsylvania Oncology Hematology Associates
1226
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
1127
mi
from
Washington,
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
1127
mi
from
Washington,
Click here to add this to my saved trials
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
413
mi
from
Saint Louis, MO
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
413
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue
The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue.
Status: Enrolling
Updated:  12/31/1969
University of Texas Medical Branch
607
mi
from
Galveston, TX
The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue
The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue.
Status: Enrolling
Updated: 12/31/1969
University of Texas Medical Branch
607
mi
from
Galveston, TX
Click here to add this to my saved trials
Wide Diameter Bone Anchored Implant Study
A Clinical Study of the Oticon Medical Ponto 4.5mm Wide Implant
Status: Enrolling
Updated:  12/31/1969
Silverstein Institute
1141
mi
from
Sarasota, FL
Wide Diameter Bone Anchored Implant Study
A Clinical Study of the Oticon Medical Ponto 4.5mm Wide Implant
Status: Enrolling
Updated: 12/31/1969
Silverstein Institute
1141
mi
from
Sarasota, FL
Click here to add this to my saved trials
Wide Diameter Bone Anchored Implant Study
A Clinical Study of the Oticon Medical Ponto 4.5mm Wide Implant
Status: Enrolling
Updated:  12/31/1969
Michigan Ear Institute
829
mi
from
Farmington Hills, MI
Wide Diameter Bone Anchored Implant Study
A Clinical Study of the Oticon Medical Ponto 4.5mm Wide Implant
Status: Enrolling
Updated: 12/31/1969
Michigan Ear Institute
829
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
636
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial)
Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most?
Status: Enrolling
Updated:  12/31/1969
University of Colorado Anschutz Medical Campus/University of Colorado Denver
400
mi
from
Aurora, CO
Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial)
Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most?
Status: Enrolling
Updated: 12/31/1969
University of Colorado Anschutz Medical Campus/University of Colorado Denver
400
mi
from
Aurora, CO
Click here to add this to my saved trials
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
803
mi
from
Atlanta, GA
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
1410
mi
from
Seattle, WA
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire
Status: Enrolling
Updated:  12/31/1969
Duke Health Center
1051
mi
from
Durham, NC
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire
Status: Enrolling
Updated: 12/31/1969
Duke Health Center
1051
mi
from
Durham, NC
Click here to add this to my saved trials
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire
Status: Enrolling
Updated:  12/31/1969
Indiana University Oral Health Research Institute
643
mi
from
Indianapolis, IN
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire
Status: Enrolling
Updated: 12/31/1969
Indiana University Oral Health Research Institute
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire
Status: Enrolling
Updated:  12/31/1969
University of Iowa
428
mi
from
Iowa City, IA
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings
Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire
Status: Enrolling
Updated: 12/31/1969
University of Iowa
428
mi
from
Iowa City, IA
Click here to add this to my saved trials
Non-operative Management of Early Appendicitis in Children
Non-operative Management of Early Appendicitis in Children
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Non-operative Management of Early Appendicitis in Children
Non-operative Management of Early Appendicitis in Children
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
Genetic Studies in Patients and Families With Infantile Spasms
Genetic Studies in Patients and Families With Infantile Spasms
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado
400
mi
from
Aurora, CO
Genetic Studies in Patients and Families With Infantile Spasms
Genetic Studies in Patients and Families With Infantile Spasms
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado
400
mi
from
Aurora, CO
Click here to add this to my saved trials
Ganaxolone Treatment in Children With Fragile X Syndrome
A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
Status: Enrolling
Updated:  12/31/1969
M.I.N.D. Institute at University of California at Davis Medical Center
1281
mi
from
Sacramento, CA
Ganaxolone Treatment in Children With Fragile X Syndrome
A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
Status: Enrolling
Updated: 12/31/1969
M.I.N.D. Institute at University of California at Davis Medical Center
1281
mi
from
Sacramento, CA
Click here to add this to my saved trials
Ganaxolone Treatment in Children With Fragile X Syndrome
A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
Status: Enrolling
Updated:  12/31/1969
Antwerp University Hospital
4711
mi
from
Edegem,
Ganaxolone Treatment in Children With Fragile X Syndrome
A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
Status: Enrolling
Updated: 12/31/1969
Antwerp University Hospital
4711
mi
from
Edegem,
Click here to add this to my saved trials
Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy
Treatment of Post-TBI Fatigue With Light Therapy
Status: Enrolling
Updated:  12/31/1969
The Brain Injury Research Center at Icahn School of Medicine at Mount Sinai
1289
mi
from
New York, NY
Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy
Treatment of Post-TBI Fatigue With Light Therapy
Status: Enrolling
Updated: 12/31/1969
The Brain Injury Research Center at Icahn School of Medicine at Mount Sinai
1289
mi
from
New York, NY
Click here to add this to my saved trials
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
Status: Enrolling
Updated:  12/31/1969
Banner MD Anderson Cancer Center
841
mi
from
Gilbert, AZ
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
Status: Enrolling
Updated: 12/31/1969
Banner MD Anderson Cancer Center
841
mi
from
Gilbert, AZ
Click here to add this to my saved trials